---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-003387"
form_type: "8-K"
ticker: "CELU"
cik: "0001752828"
company_name: "Celularity Inc"
filed_at: "2024-01-09T23:59:59+00:00"
generated_at: "2026-06-07T01:36:28.131607+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "medium"
source: SEC EDGAR
---

# Celularity expects Q4 biomaterial/biobanking net sales up 176–193% YoY, full year up 23–27%

## Summary
- Q4 2023 net sales expected $11.4M–$12.1M, up 176–193% vs Q4 2022.
- Full year 2023 net sales expected $22.06M–$22.76M, up 23–27% vs FY 2022.
- Excludes other revenue, including the Regeneron research collaboration agreement.
- Company plans to provide 2024 revenue guidance soon; aims to boost cash flow from commercial products.
- Actual Q4 and FY 2023 net sales and total revenue to be announced later in 2024.

## SEC filing metadata
- accession: 0000950170-24-003387
- form_type: 8-K
- ticker: CELU
- cik: 0001752828
- company_name: Celularity Inc
- filed_at: 2024-01-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: medium
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1752828/000095017024003387/0000950170-24-003387-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1752828/000095017024003387/celu-20240103.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-003387
- JSON: https://secwatch.observer/filing/0000950170-24-003387.json
- Plain text: https://secwatch.observer/filing/0000950170-24-003387.txt

## Key facts
- Earnings Releases
  Celularity Inc reported fourth quarter 2023 results: revenue expected net sales ... to be in the range of $11.4 million to $12.1 million. Guidance reaffirmed.
  - Period: fourth quarter 2023
  - Revenue: expected net sales ... to be in the range of $11.4 million to $12.1 million
  - Guidance: reaffirmed
  - Result: preliminary results
  source text: Total Revenue Expectations for Fourth Quarter 2023 and Full Year 2023 Celularity expects net sales of its biomaterial products and biobanking businesses to be in the range of $11.4 million to $12.1 million for the fourth quarter 2023 and $22.06 million to $22.76 million for the full year 2023 reflecting triple-digit increases compared to the fourth quarter 2022 and
  evidence_url: https://www.sec.gov/Archives/edgar/data/1752828/000095017024003387/0000950170-24-003387-index.htm
- Earnings Releases
  Celularity Inc reported full year 2023 results: revenue expected net sales ... to be in the range of $22.06 million to $22.76 million. Guidance reaffirmed.
  - Period: full year 2023
  - Revenue: expected net sales ... to be in the range of $22.06 million to $22.76 million
  - Guidance: reaffirmed
  - Result: preliminary results
  source text: Year 2023 Celularity expects net sales of its biomaterial products and biobanking businesses to be in the range of $11.4 million to $12.1 million for the fourth quarter 2023 and $22.06 million to $22.76 million for the full year 2023 reflecting triple-digit increases compared to the fourth quarter 2022 and full year 2022, respectively. These numbers do not include
  evidence_url: https://www.sec.gov/Archives/edgar/data/1752828/000095017024003387/0000950170-24-003387-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.